Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
6.05 USD +2.37% Intraday chart for Candel Therapeutics, Inc. +11.21% +311.56%
Apr. 11 Sector Update: Health Care Stocks Decline Thursday Afternoon MT
Apr. 11 Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech
AQ
Sector Update: Health Care Stocks Decline Thursday Afternoon
MT
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug
MT
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation
DJ
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
GL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
GL
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
CI
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell
MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday
MT
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday
MT
Top Premarket Gainers
MT
Candel Therapeutics Shares Surge Premarket Following 'Positive' Phase 2 Results From Non-Metastatic Pancreatic Cancer Trial
MT
Top Midday Gainers
MT
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
GL
Candel Therapeutics, Inc. Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
CI
Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
GL
Candel Therapeutics, Inc Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
CI
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
GL
Candel Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Candel Therapeutics : Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights - Form 8-K
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CADL Stock
  4. News Candel Therapeutics, Inc.